Fig. 1From: In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell linePlot of experimental Pic50 against the predicted pIC50 of both the model building as well as the external validation setBack to article page